OpiCalc

Favorites Specialties Drugs Guidelines Most Used

All Specialties

Favorites Specialties Drugs Guidelines Most Used

Faves Specs Drugs Guides Top

7-Point Dermoscopy Checklist ABSI (Burn Severity)AGEP Score AJCC Melanoma Staging ALDEN Algorithm BWH SCC Staging Body Surface Area (BSA)Breslow & Clark Microstaging CTCAE Skin Toxicity DLQI EASI Score GAGS (Acne)HiSCR IGA IHS4 Lund-Browder Chart MSK Melanoma Nomogram Melanoma Risk Screening PASI Score POEM RegiSCAR DRESS Validation Revised Baux Score SCORAD mPASI

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required

Ready for the Bedside

Resources

About Us Editorial Policy Medical Disclaimer Privacy Policy Terms of Use Cookie Policy

Support

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

Cancer MedicineJun 8, 2026

Exploring the High‐Risk Factors of Gastric “Inflammatory Cancer Transformation” Based on Inflammatory Immune Response: Construction of RHPI Complicated With CAG Risk Prediction Model

Clinical Context

We think this might be relevant to the clinical guidance for Hidradenitis Suppurativa Clinical Response (HiSCR).

WHO NewsJun 5, 2026

Africa CDC and WHO launch joint continental Ebola response plan

Clinical Context

We think this might be relevant to the clinical guidance for Hidradenitis Suppurativa Clinical Response (HiSCR).

WHO NewsMay 31, 2026

Joint statement by the Government of the Democratic Republic of the Congo and WHO concerning the outbreak of Ebola disease caused by the Bundibugyo virus

Clinical Context

We think this might be relevant to the clinical guidance for Hidradenitis Suppurativa Clinical Response (HiSCR).

HiSCR

HiSCR: The gold standard clinical response endpoint for Hidradenitis Suppurativa trials.

Baseline (Pre-treatment)

Abscess/Nodules (AN)

0

Abscesses

0

Draining Tunnels

0

Current Evaluation

Abscess/Nodules (AN)

0

Abscesses

0

Draining Tunnels

0

Compare Baseline

Enter lesion counts from before treatment (baseline) and today (current) to see if clinical response has been achieved.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

When to Use

Evaluating the efficacy of treatments for moderate-to-severe Hidradenitis Suppurativa (HS).

Primary clinical endpoint used in Phase III biologic trials (e.g., Adalimumab, Secukinumab).

Monitoring patient response to systemic therapy in outpatient dermatology clinics.

When NOT to Use

Not intended for patients with mild HS (fewer than 3 abscesses/inflammatory nodules at baseline).

Does not measure the extent of scarring or fistulas (for staging, use Hurley Stage or IHS4).

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the IHS4 or the DLQI to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Dermatology Tools

AJCC Melanoma Staging

7-Point Dermoscopy Checklist

Revised Baux Score

Dermatology Calculators Internal Medicine Calculators Emergency Medicine Calculators

Have feedback about this calculator?Let us know.